China National Health Development Research Center under the leadership of the National Health and Family Planning Commission released the first report on performance evaluation and experience summing-up for third-party medical laboratories in mainland China on September 5. According to the report, the third-party medical test industry is developing rapidly and will achieve a scale of nearly CNY 30 billion in the next two years.
In developed markets such as the United States, Europe and Japan, the third-party medical laboratory industry is mature. In Japan, the third-party medical laboratories account for 67% of the medical test market. The report points out that the mainland China got off to a late start in the third-party medical test sector, with its first such lab emerging in the mid-1990s. Statistically, the number of independent medical laboratories for medical test and pathological diagnosis increased to 759 and 207 in 2017, with a year-on-year growth of 59% and 276%.
At present, among the enterprises that focus on third-party medical laboratories, KingMed Diognostics, Dian Diagnostics and Adicon are the top three enterprises, together accounting for nearly 70% of the third-party medical laboratory market. Although the share of the third-party medical test market in mainland China in the medical test market in China is still low, there is a huge potential market space in the future. The third-party medical laboratory market will maintain a growth of 30% to 35% from 2018 to 2020, expected to reach a scale of nearly CNY 30 billion.
In terms of the future development of the third-party medical test industry, the report points out that the construction of the third-party medical test institutions should be actively integrated with hierarchical diagnosis and treatment and construction of the medical treatment partnership system, as a beneficial supplement to the public medical service system, to improve the medical test and inspection capacity at grassroots level and promote the balanced allocation of medical and health resources.
In developed markets such as the United States, Europe and Japan, the third-party medical laboratory industry is mature. In Japan, the third-party medical laboratories account for 67% of the medical test market. The report points out that the mainland China got off to a late start in the third-party medical test sector, with its first such lab emerging in the mid-1990s. Statistically, the number of independent medical laboratories for medical test and pathological diagnosis increased to 759 and 207 in 2017, with a year-on-year growth of 59% and 276%.
At present, among the enterprises that focus on third-party medical laboratories, KingMed Diognostics, Dian Diagnostics and Adicon are the top three enterprises, together accounting for nearly 70% of the third-party medical laboratory market. Although the share of the third-party medical test market in mainland China in the medical test market in China is still low, there is a huge potential market space in the future. The third-party medical laboratory market will maintain a growth of 30% to 35% from 2018 to 2020, expected to reach a scale of nearly CNY 30 billion.
In terms of the future development of the third-party medical test industry, the report points out that the construction of the third-party medical test institutions should be actively integrated with hierarchical diagnosis and treatment and construction of the medical treatment partnership system, as a beneficial supplement to the public medical service system, to improve the medical test and inspection capacity at grassroots level and promote the balanced allocation of medical and health resources.